Advertisement

Molecular Imaging and Biology

, Volume 21, Issue 3, pp 519–528 | Cite as

Evaluation of the Relationship Between Cognitive Impairment, Glycometabolism, and Nicotinic Acetylcholine Receptor Deficits in a Mouse Model of Alzheimer’s Disease

  • Yuki Matsuura
  • Masashi UedaEmail author
  • Yusuke Higaki
  • Kohei Sano
  • Hideo Saji
  • Shuichi Enomoto
Research Article

Abstract

Purpose

In patients with Alzheimer’s disease (AD), the loss of cerebral nicotinic acetylcholine receptors (nAChRs) that are implicated in higher brain functions has been reported. However, it is unclear if nAChR deficits occur in association with cognitive impairments. The purpose of this study was to assess the relationship between nAChR deficits and cognitive impairments in a mouse model of AD (APP/PS2 mice).

Procedures

The cognitive abilities of APP/PS2 and wild-type mice (aged 2–16 months) were evaluated using the novel object recognition test. Double-tracer autoradiography analyses with 5-[125I]iodo-A-85380 ([125I]5IA: α4β2 nAChR imaging probe) and 2-deoxy-2-[18F]fluoro-D-glucose were performed in both mice of different ages. [123I]5IA-single-photon emission tomography (SPECT) imaging was also performed in both mice at 12 months of age. Furthermore, each age cohort was investigated for changes in cognitive ability and expression levels of α7 nAChRs and N-methyl-D-aspartate receptors (NMDARs).

Results

No significant difference was found between the APP/PS2 and wild-type mice at 2–6 months of age in terms of novel object recognition memory; subsequently, however, APP/PS2 mice showed a clear cognitive deficit at 12 months of age. [125I]5IA accumulation decreased in the brains of 12-month-old APP/PS2 mice, i.e., at the age at which cognitive impairments were first observed; this result was supported by a reduction in the protein levels of α4 nAChRs using Western blotting. nAChR deficits could be noninvasively detected by [123I]5IA-SPECT in vivo. In contrast, no significant changes in glycometabolism, expression levels of α7 nAChRs, or NMDARs were associated with cognitive impairments in APP/PS2 mice.

Conclusion

A decrease in cerebral α4β2 nAChR density could act as a biomarker reflecting cognitive impairments associated with AD pathology.

Key words

Alzheimer’s disease Nicotinic acetylcholine receptors 2-Deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) 5-[123I]Iodo-3-[2(S)-azetidinylmethoxy]pyridine ([123I]5IA) APP/PS2 mice 

Notes

Funding Information

This work was supported in part by a Grant-in-Aid for COE projects by MEXT, Japan, titled “Center of excellence for molecular and gene targeting therapies with micro-dose molecular imaging modalities,” a Grant-in-Aid for Challenging Exploratory Research (KAKENHI Nos. 26670562 and 16K15583) from the Japan Society for the Promotion of Science, and a grant from the Smoking Research Foundation. Yuki Matsuura gratefully acknowledged the funding received from Nagai Memorial Research Scholarship from the Pharmaceutical Society of Japan.

Compliance with Ethical Standards

Animal experiments were performed in accordance with the guidelines of the Okayama University and Kyoto University Animal Care Committees. The experimental procedures performed were approved by both care committees.

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

11307_2018_1253_MOESM1_ESM.pdf (518 kb)
ESM 1 (PDF 517 kb)

References

  1. 1.
    McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269CrossRefGoogle Scholar
  2. 2.
    Milne A, Culverwell A, Guss R, Tuppen J, Whelton R (2008) Screening for dementia in primary care: a review of the use, efficacy and quality of measures. Int Psychogeriatr 20:911–926CrossRefGoogle Scholar
  3. 3.
    McConathy J, Sheline YI (2015) Imaging biomarkers associated with cognitive decline: a review. Biol Psychiatry 77:685–692CrossRefGoogle Scholar
  4. 4.
    Yasuno F, Imamura T, Hirono N, Ishii K, Sasaki M, Ikejiri Y, Hashimoto M, Shimomura T, Yamashita H, Mori E (1998) Age at onset and regional cerebral glucose metabolism in Alzheimer’s disease. Dement Geriatr Cogn Disord 9:63–67CrossRefGoogle Scholar
  5. 5.
    Levin ED, Simon BB (1998) Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacol 138:217–230CrossRefGoogle Scholar
  6. 6.
    Alkondon M, Albuquerque EX (2001) Nicotinic acetylcholine receptor alpha 7 and alpha 4 beta 2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus. J Neurophysiol 86:3043–3055CrossRefGoogle Scholar
  7. 7.
    Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, Zerlin M (2001) Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease. Biol Psychiatry 49:279–288CrossRefGoogle Scholar
  8. 8.
    Akaike A, Takada-Takatori Y, Kume T, Izumi Y (2010) Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha 4 and alpha 7 receptors in neuroprotection. J Mol Neurosci 40:211–216CrossRefGoogle Scholar
  9. 9.
    Kihara T, Shimohama S, Urushitani M, Sawada H, Kimura J, Kume T, Maeda T, Akaike A (1998) Stimulation of alpha 4 beta 2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res 792:331–334CrossRefGoogle Scholar
  10. 10.
    Saji H, Ogawa M, Ueda M, Iida Y, Magata Y, Tominaga A, Kawashima H, Kitamura Y, Nakagawa M, Kiyono Y, Mukai T (2002) Evaluation of radioiodinated 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors. Ann Nucl Med 16:189–200CrossRefGoogle Scholar
  11. 11.
    O'Brien JT, Colloby SJ, Pakrasi S et al (2007) Alpha 4 beta 2 nicotinic receptor status in Alzheimer’s disease using 123I-5IA-85380 single-photon-emission computed tomography. J Neurol Neurosurg Psychiatry 78:356–361CrossRefGoogle Scholar
  12. 12.
    Terriere E, Sharman M, Donaghey C et al (2008) Alpha 4 beta 2-nicotinic receptor binding with 5-IA in Alzheimer’s disease: methods of scan analysis. Neurochem Res 33:643–651CrossRefGoogle Scholar
  13. 13.
    Mitsis EM, Reech KM, Bois F, Tamagnan GD, MacAvoy MG, Seibyl JP, Staley JK, van Dyck CH (2009) 123I-5IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment. J Nucl Med 50:1455–1463CrossRefGoogle Scholar
  14. 14.
    Toda T, Noda Y, Ito G et al (2011) Presenilin-2 mutation causes early amyloid accumulation and memory impairment in a transgenic mouse model of Alzheimer’s disease. J Biomed Biotechnol 2011. doi: https://doi.org/10.1155/2011/617974
  15. 15.
    Matsuura Y, Ueda M, Higaki Y, Watanabe K, Habara S, Kamino S, Saji H, Enomoto S (2016) Noninvasive evaluation of nicotinic acetylcholine receptor availability in mouse brain using single-photon emission computed tomography with 123I-5IA. Nucl Med Biol 43:372–378CrossRefGoogle Scholar
  16. 16.
    Oules B, Del Prete D, Greco B et al (2012) Ryanodine receptor blockade reduces amyloid-beta load and memory impairments in Tg2576 mouse model of Alzheimer disease. J Neurosci 32:11820–11834CrossRefGoogle Scholar
  17. 17.
    Iikuni S, Ono M, Watanabe H, Matsumura K, Yoshimura M, Harada N, Kimura H, Nakayama M, Saji H (2014) Enhancement of binding affinity for amyloid aggregates by multivalent interactions of 99mTc-hydroxamamide complexes. Mol Pharm 11:1132–1139CrossRefGoogle Scholar
  18. 18.
    Gonzalez J, Jurado-Coronel JC, Avila MF, Sabogal A, Capani F, Barreto GE (2015) NMDARs in neurological diseases: a potential therapeutic target. Int J Neurosci 125:315–327CrossRefGoogle Scholar
  19. 19.
    Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA, Van Eldik LJ (2014) Using mice to model Alzheimer’s dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet 5:88CrossRefGoogle Scholar
  20. 20.
    Poisnel G, Herard AS, El Tayara NE et al (2012) Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer’s disease. Neurobiol Aging 33:1995–2005CrossRefGoogle Scholar
  21. 21.
    Kuchibhotla KV, Lattarulo CR, Hyman BT, Bacskai BJ (2009) Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science 323:1211–1215CrossRefGoogle Scholar
  22. 22.
    Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew JNC, Bohrmann B, Malherbe P, Brockhaus M, Loetscher H, Czech C, Huber G, Bluethmann H, Jacobsen H, Kemp JA (2003) PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci 23:8989–9003CrossRefGoogle Scholar
  23. 23.
    Schliebs R, Arendt T (2011) The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221:555–563CrossRefGoogle Scholar
  24. 24.
    Jin Y, Tsuchiya A, Kanno T, Nishizaki T (2015) Amyloid-beta peptide increases cell surface localization of alpha 7 ACh receptor to protect neurons from amyloid beta-induced damage. Biochem Biophys Res Commun 468:157–160CrossRefGoogle Scholar
  25. 25.
    Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, al-Abed Y, Czura CJ, Tracey KJ (2003) Nicotinic acetylcholine receptor alpha 7 subunit is an essential regulator of inflammation. Nature 421:384–388CrossRefGoogle Scholar

Copyright information

© World Molecular Imaging Society 2018

Authors and Affiliations

  1. 1.Department of Biofunction Imaging Analysis, Graduate School of Medicine, Dentistry, and Pharmaceutical SciencesOkayama UniversityOkayamaJapan
  2. 2.Radioisotopes Research LaboratoryKyoto University HospitalKyotoJapan
  3. 3.Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical SciencesKyoto UniversityKyotoJapan
  4. 4.Next-Generation Imaging TeamRIKEN Center for Life Science TechnologiesKobeJapan

Personalised recommendations